Keywords
injectable artesunate
HPLC
Kisangani
DRC
How to Cite
Abstract
Introduction
Malaria remains a major public health problem in the Democratic Republic of Congo (DRC), where injectable artesunate is the standard treatment for severe forms. Effective treatment relies on the availability of high-quality medicines, including injectable artesunate. However, the circulation of falsified or substandard products poses a serious threat to patient care.
Purpose
This study aimed to evaluate the physicochemical quality of injectable artesunates marketed in Kisangani, based on the standards of the International Pharmacopoeia (2022) and the British Pharmacopoeia (2024).
Methods
A prospective qualitative and quantitative study was conducted from February to May 2024, involving 30 batches of injectable artesunate collected from pharmacies across the six municipalities of Kisangani. Analyses were carried out at the LACOMEDA laboratory in Kinshasa using the following analytical techniques: mass uniformity, pH determination, and High-Performance Liquid Chromatography (HPLC) for identification and assay of the active ingredient and impurities, in line with the pharmacopoeial standards.
Results
All 30 samples met the visual inspection and labelling requirements. The pH ranged from 3.62 to 4.23, while mass uniformity was within ±10%, consistent with the British Pharmacopoeia (2024). Artesunate content ranged from 95.9% to 108.1%, within the specified limits (90–110%). Impurities A, B, and C were detected in low amounts; impurity A ranged from 0.2% to 0.7%. All impurity levels remained below the acceptance thresholds defined by the International Pharmacopoeia (2022).
Conclusion
All analysed samples complied with pharmacopoeial specifications during the study period. These results underscore the importance of systematic post-marketing surveillance to prevent the distribution of substandard drugs in pharmacies in Kisangani, DRC.
References
Chikowe, I., Osei-Safo, D., Harrison, J. J. E. K., Konadu, D. Y., & Addae-Mensah, I. (2015). Quality assessment of injectable artesunate in Malawi. Malawi Medical Journal, 27(3), 98–104. https://doi.org/10.1186/s12936-015-0637-z
Cockburn, R., Newton, P. N., Agyarko, E. K., Akunyili, D., & White, N. J. (2005). The global threat of counterfeit drugs: Why industry and governments must communicate the dangers. PLoS Medicine, 2(4), e100. https://doi.org/10.1371/journal.pmed.0020100
Collins, J. C., Moles, R. J., Penm, J., & Schneider, C. R. (2020). Ethical considerations in mystery client studies of pharmaceutical sales. Bulletin of the World Health Organization, 98, 375–375A. https://doi.org/10.2471/BLT.20.250878
Dondorp, A. M., Fanello, C. I., Hendriksen, I. C., et al. (2010). Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An open-label, randomized trial. Lancet, 376, 1647–1657. https://doi.org/10.1016/S0140-6736(10)61924-1
International Pharmacopoeia (Ph. Int.). (2022). Tests and general requirements for dosage forms, pharmaceutical substances and tablets (11th ed.). World Health Organization.
IOM. (2019). Mystery client sampling: Methods and applications. Institute of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK546476/
Klayman, D. L. (1985). Qinghaosu (artemisinin): An antimalarial drug from China. Science, 228(4703), 1049–1055. https://doi.org/10.1126/science.2994982
Marini, R. D., Mbinze, J. K., Aja Montes, M. L., Debrus, B., Lebrun, P., Mantanus, J., Ziemons, E., Rohrbasser, C., Rudaz, S., & Hubert, Ph. (2010). Analytical tools to combat counterfeit drugs. Chemistry Today, 28, 10–14.
Mbinze, J. K., Kalenda Tshilombo, N., Chavez, P.-F., De Bleye, C., Sacre, P.-Y., Mavar Tayey Mbay, J., Hubert, Ph., Marini, R. D., & Ziemons, E. (2014). Near-infrared spectroscopy, a non-destructive technique to fight drug counterfeiting. Spectra Analysis, 298, 46–49.
Mbinze, J. K., Nsangu Mpasi, J., Maghe, E., Kobo, S., Mwanda, R., Mulumba, G., Bolavia Bolande, J., Bayebila, T. M., Borive Amani, M., Hubert, Ph., & Marini, R. D. (2015). Application of total error strategy to validation of accessible UV-visible spectrophotometric methods for quality control of substandard drugs. American Journal of Analytical Chemistry, 6, 106–117. https://doi.org/10.4236/ajac.2015.61012
Mbinze, J. K., Sacré, P.-Y., Yemoa, A., Mavar Tayey Mbay, J., Habyalimana, V., Kalenda, N., Hubert, Ph., Marini, R. D., & Ziemons, E. (2015). Development, validation and comparison of NIR and Raman methods for identification and assay of poor quality oral quinine drops. Journal of Pharmaceutical and Biomedical Analysis, 111, 21–27. https://doi.org/10.1016/j.jpba.2015.05.002
Memvanga, P. B., Mbinze, J. K., Rozet, E., Hubert, Ph., Préat, V., & Marini, R. D. (2014). Development of a liquid chromatography method for simultaneous quantification of curcumin, β-artether, tetrahydrocurcumin and dihydroartemisinin: Application to lipid-based formulations. Journal of Pharmaceutical and Biomedical Analysis, 88, 447–456. https://doi.org/10.1016/j.jpba.2013.11.027
National Malaria Control Program (NMCP). (2023). Report on malaria in the health zones of the Democratic Republic of Congo.
Osei-Safo, D., Agbonon, A., Konadu, D. Y., Harrison, J. J., Edoh, M., Gordon, A., & Addae-Mensah, I. (2014). Evaluation of the quality of artemisinin-based antimalarial drugs distributed in Ghana and Togo. Research and Treatment of Malaria, 2014(1), 806416. https://doi.org/10.1155/2014/806416
Pharmacopoeia British (BP). (2024). Tests and general requirements for substances of physical appearance.
Sidibé, O. I. (2011). Quality control of antimalarials in seven administrative regions of Mali by thin-layer chromatography (TLC): Operationalization of minilab kits [Doctoral thesis, University of Bamako, FMPOS].
Tivura, M., Asante, I., van Wyk, A., Gyaase, S., Malik, N., Mahama, E., Hostetler, D. M., Fernandez, F. M., Asante, K. P., Kaur, H., & Owusu-Agyei, S. (2016). Quality of artemisinin-based combination therapies available in Ghanaian markets and implications for public health. BMC Pharmacology and Toxicology, 17(1), 48. https://doi.org/10.1186/s40360-016-0089-2
United Nations Office on Drugs and Crime (UNODC). (2023). Report on threats from organized crime. https://www.unodc.org/documents/data-and-analysis/Studies/Study_on_substandard_and_falsified_medicines.pdf
World Health Organization (WHO). (2017, November 28). One in ten medicines in developing countries is substandard or falsified. https://www.who.int/en/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified
World Health Organization (WHO). (2022a). World malaria report 2022. https://www.who.int/publications/i/item/9789240040496
World Health Organization (WHO). (2022b). International standards for the treatment of drug use disorders. http://www.wipo.int/amc/en/mediation/rules/
World Health Organization (WHO). (2023). World malaria report 2023. https://www.who.int/publications/i/item/9789240064898
World Health Organization (WHO). (2024). World malaria report 2024. https://www.who.int/publications/i/item/9789240064898
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.